The performance of an homogeneous enzyme immunoassay (EMIT®) for paracetamoi (acetaminophen) äs configured for the aca® series of discretionary analysers (Du Pont de Nemours) was evaluated. The method äs initially formulated by the manufacturers gave unacceptable, performance which was improved upon, by reagent reformulation and improved kit manufacture procedures, by the manufacturer. The method was fast, precise and free from interference from a ränge of metabolites, drugs and endogenous physiological compounds. There was good correlation between this method and an enzymatic method for paracetamoi (ace taminophen). Paracetamoi (Acetaminophen) 
Introduction
The quantitation of paracetamoi (acetaminophen) in blood is an impprtant investigation in the diagnosis and management of patients suspected of taking an overdose of the drug (1) . Accurate quantitation is important in samples taken no earlier than four hours after ingestion since absorption is incomplete before four hours and available antidotes are effective if treatment is commenced within ten hours of ingestion (2) . Consequently, an assay that is both rapid and specific is required for routine use.
Amomgst the many methods available for the measurement of paracetamoi there are several which do J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 2 not offer the required specificity (3) . This specificity is offered by both gas-liquid and high performance liquid Chromatographie techniques (4, 5) . However, these are not techniques which can be held in readiness for immediate use on a twenty four hour basis. More recently method specificity has been achieved with the use of enzymes (6) and antibodies (7) .
We report an evaluation of a homogeneous enzyme immunoassay technique for the measurement of paracetamoi. The method uses the principle of enzymemultiplied immunoassay (EMIT®) with a gIucose-6-phosphate dehydrogenase (EC 1.1.1.49) label (7) and has been configured for use on the aca® series of discretionary analysers manufactured by Du Pont. The immunoassays were performed on the Du Pont aca® SX discretionary analyser (E. I. Du Pont de Nemours, Wilmington, U. S. A.). The Instrument was set up and maintained, and quality control procedures followed, exactly in accordance with the manufacturers instructions.
Reagents
The reagents conformed to the well established EMIT® (Syva, Palo Alto, U. S. A.) principle s configured for the aca® analyser Systems (8) . All of the operational parameters are fixed and all the test packs configured, by the manufacturer, to predetermined performance specifications within the constraints imposed by the operational parameters and System design.
A calibration curve was prepared by assaying six calibrators in quintuplicate and the linearisation parameters of the curve stored in the Instruments Computer. The manufacturers claim that, once calibrated, further recalibration is unnecessary for 12 weeks for a given pack lot. The reagent test packs for this evaluation were provided in two lots. Data will be presented to show that unacceptable performance of the method noted with the initial pack lot provided was improved by changes made, by the manufacturer, in the formulation of the reagents, in particular the precision of filling of the reagent bubbles in the test packs and the choice of antibody and drug-enzyme conjugate.
Enzyme mediated assay
The assay is based on the use of the bacterial enzyme aryl acyl amidohydrolase (EC 3.5.1.13) which degrades paracetamol to 4-aminophenol and acetate (6) . The 4-aminophenol is detected with o-cresol and ammoniacal copper(Il) sulphate. The method protocol is s described by Hammond et al. (9) which involves the addition of 50 μΐ of serum or plasma to 1 ml of enzyme reagent and, after incubation at room temperature for two minutes, 1 ml each of o-cresol and amraoniacal copper(II) sulphate reagents. After a further incubation for two minutes the absorbance is read at 615 nm.
Procedures and Results

Precision
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Tab. 1. Within and between batch precision for the paracetamol assay. free human serum spiked with the parent drug. Two pools were prepared from EMIT® calibrator Solutions. Two further pools were prepared from assayed quality control materials (Ortho TDM control levels II and III, Ortho Diagnostic Systems Inc., Raritan, New Jersey, U. S. A.). Aliquots of each pool were stored at -20 °C until assayed. The within batch precision was performed by assaying each pool twenty times in a continuous analytical run. The between day precision was assessed by assaying each pool on twenty working days.
Material
Within batch
The data for both pack lots are shown in table 1.
Stability of calibration
After the initial calibration, verification of this calibration was carried out at weekly intervals for the duration of the study This verification procedure was carried out for both lots of test packs provided.
The data are shown in figure 1.
Dilution Curve
A serum sample known to contain approximately 1.3 mmol/1 paracetamol was diluted in varying proportions with a paracetamol-free serum sample. Similarly the top calibrator was diluted with the zero calibrator in the same proportions s above. The resultant dilutions of the serum pools and calibrators were assayed in duplicate.
The data are shown in figure 2 . Linear regression analysis of the data gave (observed) = 0.937 χ (expected) -0.011 with a correlation coefficient f 0.996 for the serum pools, and (observed) = 0.976 χ (expected) + 0.016 with a correlation coefficient of 0.998 for the calibrators. 
Method Comparison
Using the first lot of test packs a total of 133 patient samples known to contain paracetamol, within the stated assay r nge (0.06-1.32 mmol/l), were assayed by the immuno-and enzymatic procedures. A further 25 samples were collected and assayed using the second lot of test packs and the enzymatic procedure.
The data are shown in figure 3 .
Interferences
Paracetamol metabolites
Aqueous stock Solutions of the paracetamol conjugates, the cysteine, glucuronide, mercapturate and sulphate were diluted with a seram pool containing 0.3 mmol/l paracetamol. The metabolites were diluted to three concentrations with the serum pool and the pafacetamql concentration determined in duplicate. Deionised water replaced the met bolite Solutions in the controls. 
Common drugs
The protocol described for the paracetamol metabolites was used for twenty five common drugs and compounds structurally related to paracetamol. Each drug was dissolved in an appropriate solvent to give a stock solution and the relevant solvent was used to dilute the serum pool in the controls. The potential interferent was tested at three concentrations.
No interference was observed with any of the drugs tested up to the concentration stated in table 2.
Haemolysis, icterus and lipaemia
Serum pools with elevated haemoglobin, bilirubin and triglyceride concentrations 'were shown to be drug free s were two normal serum pools. Each of the pools was spiked to paracetamol concentrations of approximately 0.3 and 1.0 mmol/l by the addition of stock aqueous paracetamol Solutions of 3.0 and 10.0 mmol/l. The haemolysed, icteric and lipaemic spiked pools were diluted with the spiked normal serum pools in varying proportions and the paracetamol concentrations in each dilution determined in duplicate.
The data are shown in figure 4.
Tab. 2. Drugs tested for interference in the paracetamol method. No interference was noted, and each drug was tested at three concentrations up to the concentrations indicated in brackets (mg/1 in all cases). 
Renal patient sera
Serum from patients with renal failure may be expected to contain raised levels of endogeneous phenolic compounds which might be expected to interfere in the assay.
A total of twenty serum samples from patients with chronic renal failure (creatinine 196-1510 μπιοΙ/1) were tested in a recovery experiment with the addition of paracetamol to 0.5 mmol/l. Deionised water replaced the paracetamol in the controls.
The recovery of paracetamol was within the r nge 95 to 111 % with a mean of 102% for the twenty samples.
Discussion
Methods for the measurement of paracetamol should be rapid and specific since clinical experience in the management of patients who have taken an overdose of paracetamol suggests that s ccessful tre tinent depends on quantitation of the parent drug between four and ten hours after drug irigestion (10).
The homogeneous enzyme immunoassay for paracetamol s° configured for the aca® series of discrete analysers described offers a rapid, sp.ecific and precise method for the parent drug. *
;
Initially the precision of the assay, especially at paracetamol concentrations close to the top calibrator, was unacceptable. This was reflected in the variability of the value of the top calibrator observed in the weekly calibration checks and probably also accounted for the spread of points in the method comparison. The second lot of test packs, which were prepared to overcome this initial imprecision, by increasing the rate of absorbance change differential between the 1.0 and 1.3 mmol/1 paracetamol calibrators, improved the precision dramatically (tab. 1). As was expected, the variability in the top calibrator value observed in the weekly calibration checks also became less.
Apart from these problems the assay showed good analytical recovery and was unaffected by a r nge of metabolites. This latter group are perhaps the most important interferents to consider s in several methods they lead to the overestimation of the drug concentration by hydrolysis of the metabolites to parent drug (3, 10) . No significant interference was found with compounds administered s antidotes to paracetamol poisoning nor with any of twenty five commonly prescribed drugs. There was no significant interference from the physiological interferents haemoglobin, lipaemia or bilirubin. In the case of the high paracetamol pool spiked with these compounds the variability can be attributed to the poor precision of the method at this concentration seen with the first pack lot provided. Samples from patients with chronic renal failure (creatinine 196 -1510 μιηοΐ/l) were also without effect. The homogeneous immunoassay described offers an alternative rapid method for the determination of paracetamol. In common with the enzymatic assay (9) it is specific for the parent compound, a specificity which has been, to date, offered by the Chromatographie procedures. The combination of the described assay with a fully automated System such s the Du Pont aca® series of analysers, where strict control of all aspects of the analytical System, e. g. temperature, pipetting, absorbance measurement and reagent manufacture are possible, yields a highly stable and precise assay for paracetamol.
